---
layout: default
title: Cefditoren
parent: 僅模型預測 (L5)
nav_order: 153
evidence_level: L5
indication_count: 10
---

# Cefditoren
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Cefditoren: From Bacterial Infections to Osteoarthritis Susceptibility

## One-Sentence Summary

Cefditoren is a third-generation cephalosporin antibiotic used to treat bacterial infections of the respiratory tract and skin/soft tissue, working by inhibiting bacterial cell wall synthesis through covalent binding to Penicillin-Binding Proteins (PBPs).
The TxGNN model predicts it may be effective for **Osteoarthritis Susceptibility**,
however, **no clinical trials** and **no published literature** currently support this direction — making this a model-only prediction at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Bacterial infections (respiratory tract, skin/soft tissue) |
| Predicted New Indication | Osteoarthritis Susceptibility |
| TxGNN Prediction Score | 99.16% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Cefditoren is a β-lactam antibiotic that exerts its antibacterial effect by covalently binding to Penicillin-Binding Proteins (PBPs), thereby blocking peptidoglycan cross-linking and preventing bacterial cell wall synthesis. This mechanism is highly specific to bacterial targets and has no known downstream effects on mammalian cartilage biology, matrix metalloproteinases (MMPs), or joint tissue homeostasis.

Osteoarthritis susceptibility is a multifactorial condition driven by mechanical stress, cartilage metabolic imbalance, and genetic predisposition. There is no established biological pathway through which β-lactam antibiotics could modify disease onset or progression. While some antibiotic classes (notably macrolides) exhibit immunomodulatory and anti-inflammatory properties relevant to joint disease, Cefditoren does not share these characteristics.

The high TxGNN score most likely reflects the dense interconnectivity of musculoskeletal-related nodes within the knowledge graph rather than a true mechanistic signal. An indirect hypothesis involving gut microbiome modulation leading to reduced systemic inflammation and joint protection is biologically conceivable but lacks any experimental or clinical evidence to date and therefore does not constitute a tractable repurposing rationale.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for Cefditoren in osteoarthritis susceptibility, rheumatoid arthritis, osteoarthritis, or any of the other predicted indications.

---

## Literature Evidence

Currently no related literature available for Cefditoren in any of the predicted indications.

---

## India Market Information

Cefditoren is **not currently marketed in India**. No CDSCO-approved registrations are on record (0 licenses). There are no approved products to reference.

---

## Safety Considerations

Please refer to the package insert for safety information. No structured warning, contraindication, or drug interaction data was available in this evidence pack.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All 10 predicted indications are at Evidence Level L5 (model prediction only, zero supporting trials or publications), and the top-ranked indication — osteoarthritis susceptibility — has no plausible mechanistic connection to Cefditoren's β-lactam/PBP mechanism of action. Several lower-ranked predictions involve rare genetic skeletal disorders and chromosomal deletions that are biologically unreachable by any small-molecule antibiotic, strongly suggesting knowledge-graph topological artefacts rather than true repurposing signals.

**Before any further evaluation, the following is needed:**

- **Formal MOA documentation**: Retrieve Cefditoren's full pharmacology profile from DrugBank (DB01066) to confirm or rule out any off-target anti-inflammatory activities
- **CDSCO/India regulatory status clarification**: Determine whether Cefditoren is available under any import or compassionate-use pathway
- **Hypothesis generation step**: If this drug is to be explored for non-infectious indications, a credible mechanistic hypothesis (e.g., microbiome-mediated immunomodulation) must first be proposed and supported by at least preclinical data before proceeding to evidence collection
- **Re-ranking review**: Consider whether the TxGNN graph embeddings for Cefditoren are being dominated by musculoskeletal node co-occurrence in the knowledge graph; a calibration check against known β-lactam repurposing precedents is recommended
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

